Evidence map›Paper›PMID 38283838›Full record

ReviewFrontiers in pharmacology2023

Therapeutic approaches for chronic hepatitis C: a concise review.

Allah Nawaz, Azhar Manzoor, Saeed Ahmed, Naveed Ahmed, Waseem Abbas, Mushtaq Ahmad Mir, Muhammad Bilal, Alisha Sheikh, Saleem Ahmad, Ishtiaq Jeelani and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Allah NawazJoslin Diabetes Center, Harvard Medical School, Harvard University, Boston, MA, United States.
Azhar ManzoorDepartment of Surgery, Bahawal Victoria Hospital, Bahawalpur, Pakistan.
Saeed AhmedDepartment of Medicine, and Surgery, Rawalpindi Medical University, Rawalpindi, Punjab, Pakistan.
Naveed AhmedDepartment of Pharmacy, University of Poonch Rawalakot, Rawalakot, Azad Jammu and Kashmir (AJ&K), Pakistan.
Waseem AbbasDepartment of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Mushtaq Ahmad MirDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Muhammad BilalFirst Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.
Alisha SheikhJammu Institute of Ayurveda and Research, University of Jammu, Jammu, India.
Saleem AhmadCardiovascular Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA, United States.
Ishtiaq JeelaniDepartment of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Takashi NakagawaDepartment of Molecular and Medical Pharmacology, Faculty of Medicine, University of Toyama, Toyama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) infection is a significant global health concern, prompting the need for effective treatment strategies. This in-depth review critically assesses the landscape of HCV treatment, drawing parallels between traditional interferon/ribavirin therapy historically pivotal in HCV management and herbal approaches rooted in traditional and complementary medicine. Advancements in therapeutic development and enhanced clinical outcomes axis on a comprehensive understanding of the diverse HCV genome, its natural variations, pathogenesis, and the impact of dietary, social, environmental, and economic factors. A thorough analysis was conducted through reputable sources such as Science Direct, PubMed, Scopus, Web of Science, books, and dissertations. This review primarily focuses on the intricate nature of HCV genomes and explores the potential of botanical drugs in both preventing and treating HCV infections.

Indexed as

botanical drugsdirect-acting antiviral agents (DAAs)hepatitis Chepatitis C virushepatoprotective and antiviral properties of medicinal plants

Identifiers

PMID38283838
PMCPMC10811011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.